BAT Shares Surge Amid FDA Developments and Investor Optimism
British American Tobacco (BAT) saw its London-listed shares rise by a cumulative 13.99% last week, climbing from 4,267 pence on May 8 to 4,864 pence on May 15. Key factors driving market attention included the U.S. FDA’s recent authorization of flavored ENDS products under the Glas brand, the dismissal by a U.S. court of a criminal case against BAT regarding sanctions on North Korea, and the company’s previously announced £1.3 billion share buyback program. Analysts believe that while the FDA’s decision did not directly involve BAT’s Vuse products, it has shifted market expectations regarding the regulatory landscape for flavored e-cigarettes in the United States. Concurrently, the growth of new nicotine products—such as VELO—continues to garner significant interest from investors.
Key Highlights
BAT’s London-listed shares rose by a cumulative 13.99% last week, closing at 4,864 pence on May 15.
The U.S. FDA’s recent authorization of flavored ENDS products under the Glas brand has drawn market attention to the regulatory review environment for flavored e-cigarettes.
A U.S. court’s dismissal of a criminal case against BAT concerning sanctions on North Korea has provided a temporary alleviation of the company’s historical compliance risks.
The company previously announced a £1.3 billion share buyback program for 2026, while its new nicotine product portfolio—including VELO—continues to attract investor interest.
BAT Shares Record Strong Weekly Gains
May 18, 2026. Citing market data, Bez-Kabli.pl reports that British American Tobacco (BAT) saw its London-listed shares rise by a cumulative 13.99% last week, climbing from 4,267 pence on May 8 to 4,864 pence on May 15.
Daily, BAT’s share price rose by 5.82% on May 12—marking the largest single-day gain of the week—followed by increases of 3.73% on May 13 and 3.22% on May 14. On May 15, BAT shares retreated by 1.98%, suggesting that the market experienced some profit-taking following the consecutive days of gains.
FDA Authorization of GLAS Flavored ENDS Products Sparks Market Interest
One of the key factors underpinning the shift in market sentiment was the U.S. Food and Drug Administration (FDA)’s recent authorization of four flavored Electronic Nicotine Delivery Systems (ENDS) products under the Glas brand. This authorization does not extend to BAT’s Vuse products; however, because it involves flavored e-cigarette products, it has garnered significant attention from investors within the tobacco and e-cigarette industries.
For some time, flavored e-cigarette products in the U.S. have faced a high degree of uncertainty during the Pre-Market Tobacco Product Application (PMTA) review process. The market views this latest authorization as a key signal for observing regulatory review trends regarding flavored ENDS (Electronic Nicotine Delivery Systems) products in the U.S. Nevertheless, since the FDA’s authorization was granted to Glas, this decision cannot be directly equated to a regulatory breakthrough for BAT’s own products.
U.S. Court Dismisses BAT North Korea Sanctions Case
Beyond the regulatory landscape, BAT also achieved a significant legal milestone at the corporate level last week. Reuters reported that a U.S. judge has dismissed the criminal case against BAT regarding alleged violations of sanctions against North Korea. The U.S. Department of Justice stated that BAT has fully complied with the terms of its 2023 Deferred Prosecution Agreement.
Under the terms of the previous agreement, BAT agreed to pay approximately $630 million in fines and forfeitures, as well as to strengthen its internal compliance procedures. Following the dismissal of the case, market concerns regarding BAT’s historical legal and compliance risks have largely subsided.
Share Buyback Program Supports Investor Confidence
BAT previously announced plans to implement a share buyback program of up to £1.3 billion in 2026. For investors, this buyback program serves as an indication that the company continues to possess robust cash flow and strong capital return capabilities.
Meanwhile, BAT’s new nicotine product business continues to be a focal point of market interest. The company’s Vuse brand is one of the leading e-cigarette brands in the U.S. market, while VELO competes in the oral nicotine market against brands such as ZYN, produced by Philip Morris International (PMI). The key question for the market is whether BAT’s new nicotine business can continue to expand its growth trajectory amidst a changing U.S. regulatory environment and intensifying competition from compliant products.
Industry Analysis: Regulatory Expectations Improve, But Uncertainty Remains
From an industry perspective, the rise in BAT’s share price last week reflects a shift in the capital market’s expectations regarding the regulatory environment for new nicotine products in the U.S. The FDA’s authorization of GLAS’s flavored ENDS products has prompted investors to re-evaluate the likelihood of flavored e-cigarettes securing authorization through the PMTA pathway; concurrently, the mitigation of BAT’s legal risks and the announcement of its share buyback program have provided additional support at the corporate level.
However, this recent market rally should still be interpreted with caution. The FDA authorization does not apply to BAT’s products; the regulation of flavored e-cigarettes in the U.S. remains a subject of public health controversy and policy uncertainty. For BAT, the long-term growth of Vuse and VELO continues to hinge on the U.S. regulatory trajectory, market competition, and whether its compliant products can sustain consumer acceptance.
